Hereditary angioedema (HAE) represents an exceptionally rare condition affecting only thousands of American patients, yet paradoxically hosts one of the most competitive pharmaceutical markets in rare disease. The landscape includes three newly approved therapies from 2025, established injectable treatments, an oral prophylactic option, and an emerging pipeline featuring long-acting antibodies and gene-editing approaches.
The Diagnosis Code Problem
HAE lacks its own dedicated ICD-10 classification, instead residing under D84.1—a catch-all category for complement deficiencies. This diagnostic umbrella encompasses over four times as many patients as actually receive HAE treatment. Building marketing audiences based solely on diagnosis codes results in reaching predominantly non-HAE populations.
The solution involves reversing the identification methodology: defining patients through actual HAE-specific therapy usage across both pharmacy and medical benefits, then validating through diagnosis codes. This treatment-based approach identified approximately 10,000 rigorously confirmed patients across four years.
Value Concentration Among Patients
Patient value distributes dramatically unevenly:
- Approximately half of treated patients receive long-term prophylaxis, representing roughly 80% of modeled 10-year value
- New prophylaxis patients demonstrate 50-70 times greater lifetime value compared to one-time rescue users
- A distinct segment exists: rescue-heavy patients constitute 8% of rescue-only users but account for 45% of rescue-only value
Persistence and Retention Challenges
Early persistence data reveals critical vulnerability: approximately 25% of new prophylaxis patients discontinue therapy within three months. This initial period determines long-term retention success.
Claims data indicates 12-month persistence around 40-50%, while published studies suggest higher rates of 53-61%. This discrepancy partly reflects free-drug and bridging programs that generate no claims documentation.
Demographics and Patient Profiles
HAE patients don’t match traditional rare disease demographics:
- Adults aged 18-49 represent approximately half of modeled value
- Patients 65+ index significantly below average
- Roughly 60% maintain commercial insurance
- Approximately two-thirds are female
- Allergy and immunology specialists initiate approximately 82% of value patients
Future Market Evolution
Emerging therapies will fundamentally alter market dynamics. Expanded oral options, longer-acting injectables reducing dosing frequency, and one-time gene-editing therapies will redefine patient lifetime value calculations.
Key Strategic Recommendations
- Identify patients through treatment patterns rather than diagnostic codes
- Allocate investment proportionally to patient value rather than headcount
- Model persistence as a range with uncertainty acknowledged
- Target clinical specialists who demonstrate concentrated value reach
Successful rare disease marketing requires precision targeting of high-value patient segments rather than broad population reach.
Originally published on LinkedIn.